Fig. 2From: Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancerCumulative survival rate of patients. AP group (n = 149; black triangles), EP group (n = 150; red circles) (ITT population). AP, amrubicin/cisplatin; CI, confidence interval; EP, etoposide/cisplatin; HR, hazard ratio; OS, overall survivalBack to article page